title: Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion.
abstract: BACKGROUND
  The presence of portal vein tumor thrombosis (PVTT) is a poor prognostic factor for patients with hepatocellular carcinomas (HCC). The purpose of this study was to determine the treatment effect of irradiation in combination with hepatic arterial infusion chemotherapy (HAIC) for these patients.
  
  
  METHODS
  We retrospectively examined the outcome of 67 HCC patients with PVTT of the main trunk or first branch who received HAIC alone or with concurrent irradiation for PVTT (CCRT).
  
  
  RESULTS
  Thirty-four patients received HAIC, and 33 patients received CCRT. The time to progression (TTP) of PVTT in the CCRT group was significantly longer than in the HAIC group (p < 0.01), and the TTP of intrahepatic nodules in the CCRT group tended to be longer than in the HAIC group (p = 0.06). The objective response rates of intrahepatic nodules (52 vs. 18%, p < 0.01) and PVTT (45 vs. 18%, p = 0.01) were both significantly higher in the CCRT group than in the HAIC group, respectively. No significant difference in overall survival was found between the two groups (p = 0.14); however, the median survival time in the CCRT group was longer than that in the HAIC group (12.4 vs. 5.7 months, respectively).
  
  
  CONCLUSIONS
  CCRT might be a promising treatment for advanced-stage HCC with PVTT. CCRT prolonged the TTP of intrahepatic nodules and PVTT, and it improved the objective response rate of intrahepatic nodules and PVTT.
authors: Department of Molecular Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama City, Okayama, 700-8558, Japan, ohnis-h1@cc.okayama-u.ac.jp.
authors: Hideki
authors: H
authors: Onishi
authors: Kazuhiro
authors: K
authors: Nouso
authors: Shinichiro
authors: S
authors: Nakamura
authors: Kuniaki
authors: K
authors: Katsui
authors: Nozomu
authors: N
authors: Wada
authors: Yuki
authors: Y
authors: Morimoto
authors: Koji
authors: K
authors: Miyahara
authors: Yasuto
authors: Y
authors: Takeuchi
authors: Kenji
authors: K
authors: Kuwaki
authors: Tetsuya
authors: T
authors: Yasunaka
authors: Yasuhiro
authors: Y
authors: Miyake
authors: Hidenori
authors: H
authors: Shiraha
authors: Akinobu
authors: A
authors: Takaki
authors: Yoshiyuki
authors: Y
authors: Kobayashi
authors: Kohsaku
authors: K
authors: Sakaguchi
authors: Susumu
authors: S
authors: Kanazawa
authors: Kazuhide
authors: K
authors: Yamamoto
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000556:secondary / Q000628:therapy*; D059248:Chemoradiotherapy / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage; D018450:Disease Progression; D018572:Disease-Free Survival; D019583:Dose Fractionation, Radiation; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007261:Infusions, Intra-Arterial; D016898:Interferon-alpha / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000473:pathology* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D011169:Portal Vein / Q000473:pathology*; D020266:Radiotherapy, Conformal / Q000009:adverse effects; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D016898:Interferon-alpha; D002945:Cisplatin; D005472:Fluorouracil